Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $924M | $964M | $980M | $996M | $1.03B | $1.07B | $1.09B | $1.14B | $1.31B | $1.52B |
| Revenue growth | — | 4.4% | 1.7% | 1.6% | 3.2% | 4.5% | 1.1% | 5.1% | 14.5% | 16.1% |
| Operating income | $60.5M | $54.1M | $56.1M | $49.0M | $48.2M | $50.9M | $31.9M | $57.5M | $89.9M | $128M |
| Operating margin | 6.6% | 5.6% | 5.7% | 4.9% | 4.7% | 4.7% | 2.9% | 5.0% | 6.9% | 8.5% |
| Net income | $50.5M | $56.2M | $59.0M | $68.2M | $41.9M | $139M | $22.4M | $66.8M | $102M | $120M |
| Net margin | 5.5% | 5.8% | 6.0% | 6.8% | 4.1% | 12.9% | 2.1% | 5.9% | 7.8% | 7.9% |
| EPS (diluted) | $3.32 | $3.69 | $3.87 | $4.44 | $2.72 | $8.99 | $1.45 | $4.34 | $6.53 | $7.67 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $90.9M | $94.5M | $98.4M | $100M | $203M | $62.4M | $8.74M | $111M | $107M | $185M |
| Capital expenditures | $62.6M | $32.3M | $29.8M | $26.4M | $21.9M | $39.4M | $30.2M | $27.9M | $27.6M | $36.4M |
| Free cash flow | $28.3M | $62.1M | $68.7M | $73.7M | $181M | $23.0M | -$21.5M | $83.3M | $79.7M | $149M |
| Share buybacks | $8.20M | $0.00 | $867K | $872K | $53.0K | $836K | $9.90M | $2.48M | $13.5M | $14.7M |
| Dividends paid | $25.8M | $28.2M | $29.8M | $31.2M | $31.9M | $32.0M | $34.6M | $35.6M | $37.0M | $38.7M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $26.3M | $59.1M | $43.2M | $50.3M | $147M | $108M | $58.7M | $107M | $76.1M | $92.8M |
| Total assets | $1.09B | $1.10B | $1.08B | $1.29B | $1.36B | $1.40B | $1.28B | $1.31B | $1.52B | $1.53B |
| Total liabilities | $418M | $393M | $346M | $508M | $564M | $495M | $398M | $400M | $541M | $452M |
| Long-term debt | $120M | $100M | $55.0M | $0.00 | — | — | — | $0.00 | $130M | $32.5M |
| Shareholders' equity | $670M | $703M | $733M | $779M | $795M | $903M | $874M | $909M | $980M | $1.07B |
| Retained earnings | $392M | $419M | $516M | $553M | $563M | $669M | $657M | $688M | $752M | $833M |
| Shares (wtd avg diluted) | 15.2M | 15.2M | 15.2M | 15.4M | 15.4M | 15.4M | 15.4M | 15.4M | 15.6M | 15.6M |
Every figure is extracted from NATIONAL HEALTHCARE CORP’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.